Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D7PFL1
|
|||
| Drug Name |
GSK3882347
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Urinary tract infection [ICD-11: GC08; ICD-10: N39, N39.0] | Phase 1 | [1] | |
| Company |
GlaxoSmithKline
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial Fimbrin D-mannose adhesin (Bact FimH) | Target Info | Antagonist | [2] |
| Bacterial Fimbrin D-mannose adhesin (Bact FimH) | Target Info | Antagonist | [3] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05138822) A Double-Blind, Double Dummy, Randomized, Phase 1b, Nitrofurantoin Controlled, Repeat Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Microbiological Response of GSK3882347 in Female Participants With Acute Uncomplicated Urinary Tract Infection. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Fimbrion Therapeutics | |||
| REF 3 | Clinical pipeline report, company report or official report of GlaxoSmithKline | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.